CompletedNCT03665038
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
This study evaluated the safety of Brexanolone for people with depression.
Medication studyAges 15–17United States
Understand this study
What did researchers investigate?
This study evaluated the safety of Brexanolone for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 15 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Tempe and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 7, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 28
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 15 Years to 17 Years
- Official registry ID
- NCT03665038
- Official title
Show the full official title
A Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression
Get this study by email
Recruitment & locations
CompletedTempe · North Little Rock · Miramar
14 more locations
- Orlando
- Pensacola
- Pinellas Park
- Pompano Beach
- Atlanta
- Decatur
- Edgewood
- Owensboro
- Flowood
- Jackson
- Chapel Hill
- Middleburg Heights
- Houston
- League City
Questions about this study
What did researchers investigate?
This study evaluated the safety of Brexanolone for people with depression.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexanolone.
Who was this study for?
This study was for people with depression. Listed age limits: 15 years to 17 years. Other eligibility criteria applied.
